An Atypical Presentation of Liver Enzyme Elevation Resulting from Bosentan Use
| Autor: | Zoheir Bshouty, Kimberley Mulchey |
|---|---|
| Přispěvatelé: | University of Manitoba |
| Jazyk: | angličtina |
| Rok vydání: | 2009 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty Side effect Article Subject Atorvastatin Hypertension Pulmonary Case Report Pharmacology Gastroenterology Diseases of the respiratory system Liver Function Tests Internal medicine Medicine Humans Aspartate Aminotransferases Adverse effect Antihypertensive Agents Aged Hyperbilirubinemia Sulfonamides medicine.diagnostic_test Dose-Response Relationship Drug RC705-779 business.industry Alanine Transaminase Bosentan medicine.disease Pulmonary hypertension Discontinuation respiratory tract diseases Dose–response relationship Female Chemical and Drug Induced Liver Injury business Liver function tests medicine.drug |
| Zdroj: | Canadian Respiratory Journal, Vol 16, Iss 5, Pp e54-e56 (2009) |
| ISSN: | 1198-2241 |
| Popis: | Hepatocellular enzyme elevation is a known side effect of both bosentan and atorvastatin. However, a rise in liver enzyme level not characteristic of either agent individually may represent a reaction to their combination or an atypical reaction to bosentan alone.The present case report describes a patient who had been taking atorvastatin for many years and was started on bosentan for chronic thromboembolic pulmonary hypertension. After 19 weeks of therapy, she developed severe liver enzyme elevation that necessitated the discontinuation of both bosentan and atorvastatin. Although the safety of reintroducing bosentan in such a case is unknown, it was reintroduced in this patient because of the severity of her disease, the demonstrated treatment benefit and the lack of alternative treatment options. On reintroduction of bosentan alone, she again demonstrated significant liver enzyme elevation – this time occurring after only two doses. The present case highlights that bosentan can cause more rapid and severe hepatocellular enzyme elevation than previously believed, thus necessitating more frequent monitoring. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text